Boost to melanoma support in WA
31 January 2020
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
One Australian dies from melanoma every five hours and WA is second only to QLD in terms of melanoma incidence across Australia.
Chairman of melanomaWA, Martin Slabbert, said the merger with Melanoma Institute Australia was exciting and would have widespread benefits for the entire West Australian community.
‘The two highly respected organisations will be working together on a regional and national level regarding awareness, education, support, and research,’ Mr Slabbert said.
‘Importantly, the alignment will also provide local, regional, and remote melanoma patients with greater access to medical specialists through Melanoma Institute Australia’s network. This coordinated approach has been well received by patients connected with melanomaWA.’
CEO of Melanoma Institute Australia, Matthew Browne, said the merger would ensure increased resources dedicated to reducing the impact of melanoma on the community in WA.
‘Melanoma Institute Australia is delighted to be merging with melanomaWA,’ Mr Browne said. ‘Melanoma is, unfortunately, Australia’s national cancer and accordingly combining organisations from west coast and the east coast gives us all the best chance of fighting this disease.
‘Joining two strong melanoma organisations immediately brings increased resources and services to melanoma patients as well as a broader coordinated reach in raising awareness about early detection and prevention strategies including sun safety.’
The first fundraising and awareness event of the combined entity will be Melanoma March which will be held in Bunbury on 15th March and at Perth’s Cottesloe Beach on 29th March. Funds raised from the family-friendly Melanoma March events will support melanoma research to pave the way for new and life-saving treatments.
A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.
The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.
The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.
Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.
Professor Long cites as a highlight of her 2-year Presidency, the phenomenal research output by SMR members who have continued to lead the cancer field despite the impact of COVID-19.
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.